Hims & Hers Health (NYSE:HIMS) Insider Patrick Harrison Carroll Sells 10,021 Shares

Key Points

• Insider Patrick Harrison Carroll sold 10,021 shares of Hims & Hers Health at an average price of $50.50, totaling approximately $506,060, and reducing his ownership by 5.57%.
• Hims & Hers Health reported a Q2 revenue of $544.83 million, which fell short of analyst expectations, and earnings per share (EPS) of $0.17, missing the consensus estimate.
• Institutional investors and hedge funds currently own 63.52% of Hims & Hers Health, with some new stakes acquired during the second quarter.

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) insider Patrick Harrison Carroll sold 10,021 shares of the stock in a transaction dated Wednesday, September 17th. The shares were sold at an average price of $50.50, for a total transaction of $506,060.50. Following the completion of the transaction, the insider directly owned 169,940 shares of the company's stock, valued at approximately $8,581,970. This trade represents a 5.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Patrick Harrison Carroll also recently made the following trade(s):

• On Wednesday, August 6th, Patrick Harrison Carroll sold 60,000 shares of Hims & Hers Health stock. The shares were sold at an average price of $53.58, for a total transaction of $3,214,800.00.

Hims & Hers Health Price Performance

Shares of HIMS stock traded up $1.54 during trading hours on Friday, hitting $57.74. The company's stock had a trading volume of 36,139,154 shares, compared to its average volume of 33,212,930. The business has a fifty day moving average of $50.51 and a 200-day moving average of $45.54. The stock has a market cap of $13.05 billion, a price-to-earnings ratio of 72.18, a P/E/G ratio of 3.40 and a beta of 2.14. Hims & Hers Health, Inc. has a twelve month low of $15.73 and a twelve month high of $72.98. The company has a current ratio of 4.98, a quick ratio of 4.46 and a debt-to-equity ratio of 1.72.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings results on Monday, August 4th. The company reported $0.17 EPS for the quarter, missing the consensus estimate of $0.18 by ($0.01). The business had revenue of $544.83 million during the quarter, compared to analyst estimates of $550.06 million. Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. The firm's revenue for the quarter was up 72.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.06 earnings per share. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, equities research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Institutional Trading of Hims & Hers Health

Several large investors have recently added to or reduced their stakes in the stock. Virtus Advisers LLC purchased a new stake in Hims & Hers Health during the 2nd quarter worth $26,000. Quaker Wealth Management LLC acquired a new position in Hims & Hers Health during the 2nd quarter valued at about $29,000. Bessemer Group Inc. lifted its stake in shares of Hims & Hers Health by 105.8% in the 2nd quarter. Bessemer Group Inc. now owns 607 shares of the company's stock worth $30,000 after acquiring an additional 312 shares during the period. Skandinaviska Enskilda Banken AB publ lifted its stake in shares of Hims & Hers Health by 408.2% in the 2nd quarter. Skandinaviska Enskilda Banken AB publ now owns 747 shares of the company's stock worth $37,000 after acquiring an additional 600 shares during the period. Finally, Spire Wealth Management acquired a new stake in shares of Hims & Hers Health in the 2nd quarter worth approximately $42,000. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have recently commented on the stock. Truist Financial lowered their price target on shares of Hims & Hers Health from $48.00 to $37.00 and set a "hold" rating on the stock in a research report on Monday, August 18th. Needham & Company LLC restated a "hold" rating on shares of Hims & Hers Health in a research report on Tuesday, August 5th. Citigroup restated a "sell" rating on shares of Hims & Hers Health in a research report on Monday, June 23rd. Canaccord Genuity Group restated a "buy" rating and set a $68.00 target price on shares of Hims & Hers Health in a research report on Friday, September 12th. Finally, Zacks Research lowered shares of Hims & Hers Health from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 19th. Two equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Reduce" and an average price target of $38.92.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.